Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
|Articles|August 28, 2014
- Head and Neck Cancers (Issue 1)
- Volume 1
- Issue 1
Unmet Needs in the Treatment of Thyroid Cancer
Author(s)Lori J. Wirth, MD
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.
Advertisement
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.
Read about molecular markers and the diagnosis of thyroid cancer > >
Articles in this issue
about 12 years ago
Immunotherapy in Head and Neck Cancersabout 12 years ago
Molecular Markers Emerge in the Diagnosis of Thyroid Cancerabout 12 years ago
Results of the SELECT Trial in Thyroid Cancerabout 12 years ago
Update on Targeted Therapies in Head and Neck Cancersabout 12 years ago
Multidisciplinary Approach to Head and Neck Cancers May Improve OutcomesAdvertisement
Related to this article
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5